Are U.S. Investors Still in Denial?
Maybe it’s the Prozac after all. During the dot-com era, some blamed the ever-levitating market on Prozac. With 28 million prescription written annually, a meaningful proportion of the investing population was on anti-depressants. Perhaps the shift in collective mood was enough to blunt caution. Now I have no idea of the use of antidepressants is […]
Read more...